Organovo Holdings, Inc. (ONVO)

[72vett]

More good news:

Item 7.01 Regulation FD Disclosure
On July 24, 2014, Organovo Holdings, Inc. (the “Company”) announced that it has entered into an agreement with Janssen Research and Development (JRD), a pharmaceutical company of Johnson & Johnson, to evaluate the use of 3D bio-printed tissue in a drug discovery setting,
outside of the Company’s work in 3D liver tissue for toxicity testing. Terms have not been disclosed.
The information furnished on this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to
the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933 or the
Securities Exchange Act of 1934, except as expressly set forth by specific reference in such a filing.